Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Anavex Life Sciences Corp. (AVXL) had Consolidated Net Income/Loss of $-5.68M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-5.68M |
|
-- |
|
-- |
|
$6.78M |
|
$-6.78M |
|
$1.12M |
|
$-5.66M |
|
$-5.66M |
|
$-5.68M |
|
$-5.68M |
|
|
Consolidated Net Income/Loss |
$-5.68M |
$-5.68M |
|
$-6.78M |
|
$-6.78M |
|
89.03M |
|
89.03M |
|
$-0.06 |
|
$-0.06 |
|
| Balance Sheet Financials | |
$132.99M |
|
-- |
|
-- |
|
$132.99M |
|
$6.37M |
|
-- |
|
-- |
|
$6.37M |
|
$126.62M |
|
$126.62M |
|
$126.62M |
|
92.67M |
|
| Cash Flow Statement Financials | |
$-7.15M |
|
-- |
|
$36.32M |
|
$102.58M |
|
$131.75M |
|
$29.17M |
|
$1.11M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
20.87 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-7.15M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-4.49% |
|
-4.49% |
|
-4.27% |
|
-4.49% |
|
$1.37 |
|
$-0.08 |
|
$-0.08 |
|